stars 1 stars 2 stars 3

Xedev is a CDMO specializing in formulation and process development for solid dosage forms, offering a faster, smarter path to the clinic. We take your promising molecule and transform it into a test-ready formulation. Our dedicated scientists cover early-phase formulation across a broad range of administration routes, with full analytical capabilities to ensure complete understanding of product quality and stability. From improving solubility and bioavailability to controlling release profiles, we navigate the complexities so your innovation reaches its full potential. Xedev has a strong formulation and analytical development team, a GMP facility and an appropriate pharmaceutical quality system, enabling manufacturing up to Phase IIb. Spray drying is one of our core strengths. What makes us different: → Fast start-up: projects begin within 6-8 weeks of customer approval → Flexible & personal: you're not a number, you're a priority → Transparent collaboration: you're always welcome to join us in the lab → Phase-appropriate approach — from preclinical R&D batches through Phase IIb We offer: ✔ Formulation & process development via drying, granulation, tableting and coating processes ✔ Analytical characterization of drug substances and drug products ✔ Clinical batch manufacturing up to Phase IIb 📍 Based in Zele, Belgium | 🌐 xedev.com Looking forward to connecting!

XEDEV Questions

The XEDEV annual revenue was $1 million in 2026.

Filip Van Der Gucht is the CEO and Founder of XEDEV.

15 people are employed at XEDEV.

The NAICS codes for XEDEV are [32, 3254, 32541, 325].

The SIC codes for XEDEV are [28, 283].

Top XEDEV Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users